Drug intelligence / Profile preview

letrozole + atorvastatin

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

Letrozole + atorvastatin is a combination of two small molecule drugs, each with distinct mechanisms of action and primary indications. Letrozole is a nonsteroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women by inhibiting estrogen synthesis. Atorvastatin is an HMG-CoA reductase inhibitor (statin) indicated for lowering lipid levels and reducing cardiovascular risk by inhibiting cholesterol biosynthesis. While both drugs are sometimes co-prescribed—particularly in patients with breast cancer who develop hypercholesterolemia as a side effect of aromatase inhibitors—there is no evidence that they are formulated or marketed as a fixed-dose combination product. No clinically significant pharmacokinetic or pharmacodynamic interactions have been reported between these two agents[1][3][4]. Both drugs have also shown anti-inflammatory and pro-apoptotic effects in experimental models, such as endometriosis[7].

02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on letrozole + atorvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on letrozole + atorvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call